{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:28:17Z","timestamp":1730870897997,"version":"3.28.0"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Diagnosestellung Die 2021 erschienene Herzinsuffizienz-Leitlinie der Europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie (ESC) hat die Diagnosestellung etwas vereinfacht. Sie listet die Diagnosekriterien gleichwertig, ohne das Vorliegen einer bestimmten Anzahl von Kriterien zu fordern.<\/jats:p><jats:p>\n            \u00c4tiologie Eine Expertengruppe der Herzinsuffizienz-Vereinigung (HFA: Heart Failure Association) und der Rhythmus-Vereinigung (EHRA: European Heart Rhythm Association) der ESC sowie der Europ\u00e4ischen Gesellschaft f\u00fcr Hypertonie unternahm den Versuch, durch detaillierte Ph\u00e4notypisierung pathophysiologisch und therapeutisch distinkte Profile an HFpEF-Patienten herauszuarbeiten.<\/jats:p><jats:p>\n            Therapie In einem unl\u00e4ngst erschienenen Update der Leitlinie wurden auf der Basis neu gewonnener Evidenz erstmals konkrete Empfehlungen zur Pharmakotherapie der HFpEF formuliert. Die Kontrolle der Risikofaktoren und ein gesunder Lebensstil bleiben weiterhin von gro\u00dfer therapeutischer Bedeutung.<\/jats:p>","DOI":"10.1055\/a-2096-7448","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:29:48Z","timestamp":1709080188000},"page":"314-319","source":"Crossref","is-referenced-by-count":0,"title":["Update: Herzinsuffizienz mit erhaltener Pumpfunktion"],"prefix":"10.1055","volume":"149","author":[{"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Deutsches Zentrum f\u00fcr Herzinsuffizienz, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Deutsches Zentrum f\u00fcr Herzinsuffizienz, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"B Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","author":"TA McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"SD Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"155655","DOI":"10.1016\/j.metabol.2023.155655","article-title":"Effect of bariatric surgery on cardio-psycho-metabolic outcomes in severe obesity: A randomized controlled trial","volume":"147","author":"AC Koschker","year":"2023","journal-title":"Metabolism"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"MN Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"SD Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"SD Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"SD Solomon","year":"2020","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/eurheartj\/ehz550","article-title":"Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?","volume":"41","author":"GJ Wehner","year":"2020","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.36660\/abc.20190835","article-title":"Heart Failure with Supra-normal Left Ventricular Ejection Fraction \u2013 State of the Art","volume":"116","author":"Z Huang","year":"2021","journal-title":"Arq Bras Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"E Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/ehjci\/jead036","article-title":"Spatial relationship between mitral valve and ventricular septum assessed by resting echocardiography to diagnose left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"24","author":"N Verheyen","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"SD Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"SD Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"DL Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes","volume":"146","author":"G Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"M Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","article-title":"Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age","volume":"80","author":"M Bohm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"WT Abraham","year":"2011","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)","volume":"22","author":"CE Angermann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week","volume":"77","author":"M Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"AD Wechalekar","year":"2022","journal-title":"JACC CardioOncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"A Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"I Olivotto","year":"2020","journal-title":"Lancet"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2096-7448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:13:18Z","timestamp":1730815998000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2096-7448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":25,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,2,27]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2096-7448","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}